Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation

Annals of the Rheumatic Diseases

Volumn 72, Issue 1, 2013, Pages 104-109

  Van Schouwenburg, Pauline A ^a   Van De Stadt, Lotte A ^a,b,c   De Jong, Rob N ^d   Van Buren, Esther E L ^d   Kruithof, Simone ^a   De Groot, Els ^a   Hart, Margreet ^a   Van Ham, S Marieke ^a   Rispens, Theo ^a   Aarden, Lucien ^a   Wolbink, Gerrit Jan ^a,b,c   Wouters, Diana ^a  

^a SANQUIN RESEARCH   (Netherlands)

^b Jan Van Breemen Research Institute/Reade   (Netherlands)

^c Cell and Molecular Science Department   (Netherlands)

^d GENMAB   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIIDIOTYPIC ANTIBODY; CROSS REACTING ANTIBODY; DRUG ANTIBODY; INFLIXIMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ADALIMUMAB 1.1; MONOCLONAL ANTIBODY ADALIMUMAB 1.2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS REACTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY COMPLEX; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS;

EID: 84871091638     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201445     Document Type: Article

References (18)

1. Schellekens H. The immunogenicity of therapeutic proteins. Discov Med 2010;49:560-4.
2. Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007;14:1391-403. (Pubitemid 47511460)
3. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;14:1460-8.
4. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;7:601-8. (Pubitemid 36204954)
5. Aarden L, Ruuls SR, Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 2008;4:431-5.
6. McInnes IB, O'Dell JR. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 2010;11:1898-906.
7. Saber TP, Veale DJ. Psoriatic arthritis management update - biotherapeutic options. J Rheumatol Suppl 2009;83:65-8.
8. Shah B, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. Expert Rev Clin Immunol 2010;4:607-20.
9. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;7:921-6. (Pubitemid 46999794)
10. de Vries MK, Brouwer E, van der Horst-Bruinsma IE, et al. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis 2009;11:1787-8.
11. Jamnitski A, Bartelds GM, Nurmohamed MT, et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 2011;2:284-8.
12. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009;5:1628-40.
13. Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2008;86:1739-45.
14. van Kuijk AW, de GM, Stapel SO, et al. Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis 2010;3:624-5.
15. van Schouwenburg PA, Bartelds GM, Hart MH, et al. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals 'hidden' immunogenicity in rheumatoid arthritis patients. J Immunol Methods 2010;1-2:82-8.
16. Jerne NK. Towards a network theory of the immune system. Ann Immunol (Paris) 1974;1-2:373-89.
17. Jerne NK. The generative grammar of the immune system. Science 1985;4718:1057-9. (Pubitemid 15013175)
18. Korswagen LA, Bartelds GM, Krieckaert CL, et al. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum 2011;4:877-83.